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Background: Podocytes can be the primary site of injury or secondarily involved in various protienuric states. Cross
talk between adjacent foot processes and with basement membrane is important for slit diaphragm function. Does
expression of podocyte associated proteins in kidney biopsies alter with site/type of primary injury? Genetic mutations
of podocin result in steroid resistant FSGS. Can protein expression of podocin predict resistant cases to initiate further
genetic evaluation?
Methods: Adult patients (n-88) with protienuria- minimal change disease(MCD)-22, focal segmental glomerulosclerosis
(FSGS)-21,membranous glomerulonephritis(MGN)-25 and IgA nephropathy(IgAN)-20 were selected for
immunohistochemistry with podocin and beta dystroglycan . Results were graded (0 - 3+scale )and compared with
control biopsies and internal control. Treatment and follow up (6 months -2 ½ years) of FSGS and MCD cases were
collected.
Results: There was intense to moderate staining of the podocytes with podocin and β dystroglycan in the glomeruli
in all cases (MCD, FSGS, IgAN and MGN) except for weak staining with β dystroglycan in 3 cases of MCD. There was
loss of immunostains in areas of segmental/global sclerosis. There was no significant difference in the staining
pattern between the groups. In primary podocytopathies, staining pattern did not differ between steroid resistant,
sensitive or dependent cases.
Conclusions: Immunohistochemical expression of podocin and β dystroglycan does not differ in nephropathies
which have different site of injury depending on absence (MCD and FSGS) or presence of immune deposits and their
localization (MGN and IgAN). Podocin and β dystroglycan staining did not differentiate steroid sensitive and resistant
cases, hence, does not give clue to initiate genetic studies. However, analysis of bigger cohort may be required.
Summary: Podocin and β dystroglycan immunohistochemistry was done to analyze podocyte - podocyte and
podocyte -basement membrane matrix connections in adult protienuric states. Primary podocytopathies i.e. MCD and
FSGS and secondary podocytopathy due to immune complex deposition i.e. MGN (subepithelial) and IgAN (mesangial)
were analyzed. There was no difference in staining patterns between primary and secondary podocytopathies or
between steroid sensitive, resistant and dependent cases of FSGS and MCD.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2258608781052786
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Podocyte are important component of glomerular filtra-
tion barrier. There are primary podocytopathies where
podocytes are aetiopathogenetically associated with the
pathology i.e. MCD and FSGS. Podocytes can be second-
arily involved and contribute to protienuria in diseases
where primary site of injury is not podocyte e.g. mem-
branous with sub epithelial immune complex deposits
and IgAN with dominant mesangial immune deposits
[1,2]. Podocyturia as a marker of disease activity has
been reported in various protienuric states including
FSGS, IgAN and MGN using various podocyte specific
proteins [3] but not in MCD [4]. However, integrins
including α and β dystroglycan which determine the at-
tachment of podocytes to basement membranes have
been shown to be reduced in steroid sensitive MCD and
suggested to be useful in distinguishing FSGS, MCD and
unrepresented FSGS [5-8]. Podocin being specific marker
to identify podocytes in studies conducted for podocyturia,
it might be worthwhile to study its expression in kidney
biopsy in these protienuric states.
Various other podocyte associated proteins are being
studied in these protienuric states using different methods
yielding variable results [5-12]. Previous studies have been
conducted in relatively smaller cohorts and composition of
the cohorts in most of these studies were heterogeneous,
comprising of both pediatric and adult patients; it is a
known fact that aetiopathogenesis and clinical progression
of nephropathies is different in adults and children. To ex-
plore answers to these questions we conducted this study
on a cohort of 80 adult patients.
Podocin is one of the slit diaphragm proteins and
mutations of its genes have been associated with non
Finnish type of congenital and infantile nephrotic
syndrome [13-16] and as steroid resistant nephrotic syn-
drome in relatively older siblings (up to 7 years) in such
families [13]. Renal morphology is such cases can min-
imal glomerular changes or FSGS [13]. Mutations of
genes for podocin have been documented even in spor-
adic cases of FSGS both in pediatric (10-30%) [14,15]
and adult cohorts (<1% -12%) [17-20]. Steroids and
cytotoxic therapies in such patients should be avoided
as they are not expected to show any response. Another
clinical implication is that FSGS with genetic abnormal-
ities do not recur after transplant. Different type of
mutations ranging from nonsense, missense and frame
shift mutations have been reported which on functional
analysis, in certain situations affect podocin-nephrin
binding also [17-20]. Is there any difference in expres-
sion of podocin protein in these patients with genetic
basis of FSGS and other protienuric states which can
be identified by simpler test like immunohistochemistry
specific for the podocin to identify candidates for fur-
ther genetic studies?This study was done to find whether podocin and beta
dystroglycan protein expression differs in podocytopa-
thies (primary and secondary- immune complex induced)
in adults and will they help to differentiate between the
two primary podocytopathies i.e. MCD and FSGS. Can
pattern of expression of these proteins indicate steroid re-
sistant non familial nephrotic syndrome? Whether
these markers can predict response to steroid therapy?
In protienuric conditions with podocyturia, is there
altered expression of integrins i.e. beta dystroglycan,
the adhesion molecules between podocytes and base-
ment membrane.
Subjects and methods
Eighty eight consecutive cases of adult patients who
presented with nephrotic/subnephrotic range protie-
nuria with (FSGS-21, IgAN-20) or without nephritic
picture (MCD-22, MGN-25) between 1.1.2009- 30.9.2012
were chosen from the files of department of Histo-
pathology, PGIMER Chandigarh. Thin needle core like
tissue from nephrectomy specimens done for renal
tumors and zero hour transplant biopsies were used
as control with each batch of slides stained (each batch
n-10). The clinical details and investigations were re-
trieved from the files of department of Nephrology,
PGIMER. All the biopsies were analyzed by light micros-
copy, immunofluorescence and electron microscopy by
two nephropathologist (KJ and RN). Only FSGS-NOS
variant were included in this study. Since we intended
to study podocytes in mesangial disease, cases of IgAN
preferably with only/dominant mesangial deposits were
included.
Immunohistochemistry for podocin and beta dystro-
glycan was performed using Rabbit Anti-human mono-
clonal IgG antibody. Antigen retrieval was done by heat
retrieval under pressure using pressure cooker method.
Primary antibody for Beta dystroglycan (Cat no.VP-
B205, Vector laboratory) was used at a concentration
of 1:30, while podocin (Cat podo 11-A Alpha diagnostic
laboratory) was used at a dilution of 1:50. The secondary
antibody tagged with peroxidase was used and color was
developed with DAB. One control slide was stained with
each batch.
Immunohistochemical staining in the glomeruli was
compared with control biopsies and/or internal control,
and graded on a scale of 0 to 3+. Control cases showed
2+ staining of podocytes and of distal tubular basement
membrane with β-dystroglycan (Figure 1a). With podo-
cin glomeruli and smooth muscles cells of blood vessels
showed 2+ positivity with podocin (Figure 2a). Any glo-
bal or segmental loss of expression of these podocyte
proteins was noted, and the number of glomeruli affected
was recorded. Staining in tubular basement membrane also




Figure 1 Photomicrograph shows beta dystroglycan expression (2+) in the glomeruli & tubules (arrows) a) Control (20X) b) MCD (10X)
c) FSGS-normal glomerulus (20X) d) FSGS-loss of staining in sclerosed area (arrow head) (X40) e) IgAN (X40) f) MGN (20X) IHC, beta
dystroglycan antibody.
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staining while 2+ and 3+ were considered to be positive
staining.
Treatment and follow up history (6 months-2 ½ years)
of FSGS and MCD cases was collected. They were classi-
fied as steroid sensitive, steroid resistant or steroid
dependent groups. Follow up history was available in ten
cases of MCD and twelve cases of FSGS. Of these cases
with follow up, all the MCD cases were steroid sensitive.
Eight of the twelve (66.6%) FSGS cases with follow upwere steroid sensitive, three (25%) were steroid resistant
and one was steroid dependent.
Post Graduate Institute of Medical Education and
Research, Chandigarh, India had approved this study
(reference no 7545-PG-Ttrg/2009 dated 26.11.2009).
Statistics
The statistical analysis was carried out using Statistical
Package for Social Sciences (SPSS Inc., Chicago, IL,





Figure 2 Photomicrograph shows podocin expression (2+) in all except 1+ intensity in MCD (inset b) and loss of staining in FSGS (d)
a) control b) MCD c) & d) FSGS e) IgAN f) MGN) IHC, Podocin, X20.
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or Kruskal Walis test (for variables with more than
two groups) were applied. Qualitative or categorical vari-
ables were described as frequencies and proportions. Pro-
portions were compared using chi square test wherever
applicable. All statistical tests were two-sided and per-
formed at a significance level of α = 0.05
Results
Patients were categorized as with nephrotic or subne-
phrotic range protienuria with or without nephritic fea-
tures. Nephritic presentation was most frequent in IgANcases. There was no significant difference in the clinical
and laboratory parameters in the other categories. The
clinical and laboratory parameters at the time of diagno-
sis are summarized in the Tables 1 and 2.
Immunohistochemistry for beta dystroglycan
There was intense (3+) to moderate (2+) staining of the
podocytes along glomerular basement membranes in all
cases of FSGS, IgAN and MGN. Tubular basement
membranes and control cases served as internal and
external controls respectively. There was no significant dif-
ference in the staining intensity between different groups
Table 1 Summary of clinical and laboratory findings
MCD FSGS IgAN MGN P value
Mean ± SD Min Max Mean ± SD Min Max Mean ± SD Min Max Mean ± SD Min Max -
Age (years) 30±10.98 14 60 34±15.93 14 72 28±9.83 14 45 41±13.63 20 62
Sex Male 12 12 11 16
Female 10 9 9 9
24 hour urine protein (gms/24hours) 3.44±1.56 0.40 6.80 3.52±2.05 0.64 10.00 3.40±1.60 0.70 5.00 3.51±1.19 1.80 6.00 0.985
Serum creatinine (mg/dl) 1.19±0.54 0.40 2.60 1.41±0.61 0.50 2.30 1.43±1.46 0.57 3.20 1.17±0.68 0.50 3.20 0.611
Hypertension Non Hypertensive 18 16 10 17 0.519
Hypertensive 4 5 7 5
Proteinuric range Nephrotic (24 hours urine
protein > 3gms)
17 20 2 23 <0.001*
Sub nephrotic (24hours urine
protein 0.5 to 3 gms)
4 0 3 0
Nephritic (hematuria +
proteinuria)
1 1 15 2
Steroid responsiveness Steroid sensitive 10 8 - - -
Steroid resistant 0 3 - -
Steroid dependent 0 1 - -
Note; MCD-Minimal change disease, FSGS-focal segmental glomerulosclerosis, IgA N-IgA nephropathy, MGN-Membranous glomerulonephritis, min-minimum,















Table 2 Significant additional demographic information
of patients
MCD FSGS IgAN MGN
Diabetes 0 2 0 1
Malformations 0 0 0 0
Infections 0 0 2 Pustules Hepatitis C 0
Profession 0 Factory worker Student -3 0
Exposure 0 Asbestosis 0 0
Alternative
medicine
1 2 0 1
Note; MCD-Minimal change disease, FSGS-focal segmental glomerulosclerosis,
IgA N-IgA nephropathy, MGN-Membranous glomerulonephritis.
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glycan in areas of segmental/global sclerosis in various
groups. There was intense(3+) to moderate(2+) staining of
the podocytes along glomerular basement membranes in
all cases of MCD also except that 3 cases had 1+ staining
(which is considered as weak). Table 3, Figure 1.
Cases of MCD with loss of staining were not different
from other patients; there was no correlation between
the β-dystroglycan staining intensity and degree of pro-
teinuria (1.80, 4.20, 5.00gm/24 hours, p-0.638), or renal
function assessed by the serum creatinine levels(0.8, 0.9,
1.10 mg/dl, p-0.491). Follow up history was available in
these cases and were steroid sensitive. Immunohisto-
chemistry for podocin was positive (2 + -3+) in these
three cases.
Tubular basement membrane staining was variable
between groups, both in terms of overall number of tu-
bules stained and the intensity of proximal convoluted
tubules (PCT) and distal convoluted tubules (DCT) stain-
ing; these differences were statistically significant (p <0.001
and, 0.009 respectively). Table 2 Overall number of tubules
stained (more than two third) with beta dystroglycan were
more (half to two third cases) in MGN, IgAN, FSGS as
compared to MCD (one fourth). Tubules with intense
staining in MCD were PCT as compared to other groups
where intense staining was localized to DCT (Table 3).
Immunohistochemistry for podocin
There was intense(3+) to moderate(2+) staining of the
podocytes with podocin along glomerular basement
membranes in all cases of MCD, FSGS, IgAN and mem-
branous glomerulopathy. Control cases served as external
controls with each batch of stain. There was no cases with
negative staining or weak(1+) staining in any of other
groups. There was loss of immunostain for podocin in
areas of segmental/global sclerosis in various groups.
There was no significant difference in the staining pattern
between the groups (p value 0.5). There was no difference
in the staining pattern of the steroid resistant, steroid sen-
sitive or steroid dependent cases (p-0.45). There was nocorrelation between the podocin staining intensity and 24
hours urine protein levels (p-0.35) Figure 2.
Discussion
Podocytopathies in adults and pediatric patients are dif-
ferent aetiopathogenetically and have different rate of
disease progression and response to therapy [1,2]. In
present study we did not find any difference in expres-
sion of beta dystroglycan in the four groups of patients
presenting as protienuric states. Diseases with primary
podocytopathies (MCD and FSGS) and cases with sec-
ondary podocytopathies due to sub epithelial immune
complex formation (MGN) and mesangial immune com-
plexes (IgAN) were not different in terms of expression
of beta dystroglycan which is one of the integrins in-
volved in podocyte basement membrane interaction.
Expression of β dystroglycan, the adhesion molecule
between podocyte and basement membrane in diseases
with podocyturia (FSGS, membranous glomeruloneph-
ritis, IgAN) was not different from disease without
podocyturia (MCD. In the present study, only three out
of the 22 cases of minimal change disease showed re-
duced intensity of beta dystroglycan expression and were
steroid sensitive as were cases with intense dystroglycan
staining.
Regale et al [5] observed reduced expression of β dys-
troglycan in steroid responsive minimal change disease,
which was also substantiated with immunogold labeling
index. Their study had the limitation of few numbers of
cases and included both adult and pediatric patients.
Giannico et al in a study of adult cohort documented no
reduction in expression of beta dystroglycan in MCD,
whereas alpha dystroglycan was reduced in MCD [7].
However, Vogtlander et al documented that there was
no difference in the staining pattern of alpha dystrogly-
can in nephrotic syndrome cases [6] (Table 4).
Schmid et al [8] studied mRNA expression in adult
population, and documented that the ratio of beta dys-
troglycan mRNA/house keeper gene ratio was not al-
tered in MCD. They concluded that beta dystroglycan
gene expression may not help to differentiate MCD from
FSGS (Table 3).
In present study, observation of variable intensity and
number of tubular staining with beta dystroglycan on
immunohistochemical stain suggests that use of method-
ology like mRNA expression without taking into consid-
eration expression pattern on histology might not give
correct information about alteration of widely and vari-
ably expressed protein like beta dystroglycan.
Similarly, there was no difference in immunohisto-
chemical expression of podocin in these groups of dis-
eases i.e. primary podocytopathies (MCD and FSGS) and
cases with secondary podocytopathies MGN and IgAN.
No significant difference was observed in the Podocin
Table 3 Staining pattern of glomeruli and tubules with beta dystroglycan in MCD, FSGS, IGAN and MGN
Histological parameters Degree Groups P value
MCD FSGS IgAN MGN
Glomerular staining of Absent n(%) 4(18.1%) 4(19.0%) 4(20.0%) 1(4.0%) 0.975 NS
beta-dystroglycan Mild n(%) 4(18.1%) 3(14.2%) 6(30.0%) 4(16.0%)
Moderate n(%) 10(45.4%) 10(47.6%) 7(35.0%) 7(28.0%)
Intense n(%) 4(18.1%) 4(19.0%) 3(15.0%) 13(52.0%)
Tubules (PCT) staining pattern of Absent n(%) 8(36.3%) 5(23.8%) 15(75.00% 11(44.0%) 0.009 *
beta dystroglycan Mild n(%) 0 2(9.5%) 0 3(12.0%)
Moderate n(%) 4(18.1%) 9(42.8%) 5(25.00%) 8(32.0%)
Intense n(%) 10(45.4%) 5(23.8%) 0 3(12.0%)
Tubules (DCT) staining pattern of Absent n(%) 2(9.0%) 2(9.5) 7(35.0%) 3(12.0%) 0.92 NS
beta dystroglycan Mild n(%) 0 0 0 2(8.0%)
Moderate n(%) 6(27.2%) 5(23.8%) 7(35.0%) 7(28.0%)
Intense n(%) 14(63.6%) 14(66.6%) 6(30.0%) 13(52.0%)
% Tubular staining <30% n(%) 6(27.27%) 5(23.8%) 10(50.0%) 6(24.0%) <0.001*
30-60% n(%) 10(45.4%) 6(28.5%) 0 3(12.0%)
>60% n(%) 6(27.2%) 10(47.6%) 10(50.0%) 16(64.0%)
Note; MCD-Minimal change disease, FSGS-focal segmental glomerulosclerosis, IgA N-IgA nephropathy, MGN-Membranous glomerulonephritis, NS-not significant,
PCT-proximal convoluted tubules, DCT-distal convoluted tubules, *- statistically significant.
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variable results documented in literature which could be
due to difference in the composition of study cohorts
(pediatric patients or adults or both) or the techniques
used (Table 5).
Comparison between these studies is difficult because
most of the studies (except adult cohort by Koop et al
[9], included either only pediatric cases or included both
pediatric and adult patients. Techniques and methods of
analysis were also variable. These diseases are known to
be different aetiopathologicaly, in rate of progression and
response to therapy in adults and pediatrics; hence we
chose to study only adult patients.Table 4 Comparison of beta dystroglycan immunostaining wi
Authors β dystroglycan staining
Regale et al (2000) [5] Adults and pediatrics Total cases
Cases with +/- score
No of case with 1+ glom
Cases with 2+/3+ score
Giannico et al (2009) [9] Adults Total cases
Cases with absent stainin
Present studyAdults Total cases
Cases with 1+ score
Cases with 2+ and 3+ sc
Note: MCD-Minimal change disease, FSGS-focal segmental glomerulosclerosis, IgA N
N.A- not available.Horinouchi et al [10] (both pediatric and adult popula-
tion) observed reduced expression of podocin in FSGS
cases except for only one case which had 3+ staining for
podocin; this case with positive staining showed good re-
sponse to treatment as was observed in present study 10.
They suggested that decreased podocin expression in FSGS
cases may be associated with steroid resistance and poor
response to therapy. They also documented decreased
podocin staining in MGN and normal staining pattern be-
ing preserved in IgAN and HSP (due to mesangial nature
of the disease). It was proposed that the mesangial diseases
are less prone for the loss of podocyte associated proteins
in the glomeruli, compared to FSGS where the primaryth other studies
MCD FSGS IgAN MGN
12 8 Nil Nil
5 Nil N.A N.A
erular score 7 1 N.A N.A
Nil 4 and 3 N.A N.A
10 32 N.A N.A
g Nil Nil N.A N.A
22 21 20 25
3 Nil Nil Nil
ore in the glomeruli 2 and 17 1 and 20 3 and 17 6 and 19
-IgA nephropathy, MGN-Membranous glomerulonephritis.
Table 5 Comparison of podocin immunostain with other studies
Authors No. of cases MCD FSGS IgAN MGN Henoch Schoenlein
purpura nephritis
Horinouchi et al (2003) [10] Pediatric
and adult
Total 6 19 6 5 6
Absent staining 0 7(36.84%) 0 0 0
1+ 0 7(36.84%) 0 1(15%) 0
2+ 0 4(21.05%) 0 19(15%) 0
3+ 6(100%) 1(5.2%) 6(100%) 3(60%) 6(100%)
Mao J et al (2006) [11] Pediatric Total 9 - 6 - -
Podocin fluorescence intensity Not
reduced
Not reduced
Koop et al (2003) [6] Adult Total 10 5 10 1
Podocin IHC intensity quantification
by image analysis
Reduced Reduced Not altered Reduced -
Podocin mRNA levels Increased Increased Decreased Increased -
Guan N et al (2002) [12] Pediatric Total 9 - 4 - -





Present study Total 22 21 20 25 -
Absent staining 0 0 0 0 -
1+ 0 0 0 0 -
2+ 6(27.27%) 7(33.33%) 3(15%) 8(32%) -
3+ 16(72.72%) 14(66.66%) 17(85%) 17(68%) -
Note; MCD-Minimal change disease, FSGS-focal segmental glomerulosclerosis, IgA N-IgA nephropathy, MGN-Membranous glomerulonephritis.
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podocyte associated protein. However, this does not ex-
plain the loss of podocin expression being more in MGN
where the glomerular injury occurs at the sub epithelial
area, compared to MCD, where the podocytes are the pri-
mary targets of injury [10] (Table 5).
Mao et al [11] have reported that the expression level
of podocin is not reduced in the minimal change disease
and IgAN (pediatric population). Koop et al 9 docu-
mented reduced expression of podocin and nephrin in
protienuric states i.e. MCD, FSGS, MGN except IgAN
adult cohort). Guan et al [12] (pediatric) also recorded
reduced expression of podocin in MCD only and no al-
teration in FSGS and IgAN.
In present study, podocin expression was observed on
smooth muscles of arteries included in the biopsies,
which might have confounded the results where mRNA
expression of whole kidney biopsy was assessed.
Various studies aimed at studying the expression of
the podocyte associated proteins at the mRNA level or
the protein level have shown inconsistent results in the
expression of these proteins in acquired nephrotic syn-
drome. Similar to the differences observed in the muta-
tional status of pediatric and adult population, there
might be differences in the protein expression patterns
of pediatric and adult patients.Conclusion
Present study is a cohort of only adult patients compris-
ing of relatively large number of cases and emphasize
that there is no difference in expression of podocin and
beta dystroglycan involved in podocin-podocin interaction
and podocyte - basement membrane and in cases of both
primary and secondary podocytopathies (immune complex
mediated). These immunostains cannot be used to differ-
entiate between MCD/FSGS and predict response to ther-
apy at least in adult cases unlike documented by few
studies in literature. There is no loss of staining in steroid
resistant cases.
The molecular mechanisms underlying the pathogen-
esis of pediatric and adult nephrotic syndrome may be
markedly different. Further, molecular and immunohis-
tochemical studies on both beta dystroglycan and podo-
cin may help us to understand the role of these proteins
in the pathogenesis of primary and secondary podocyto-
pathies and to understand how to apply these markers
in the routine management of patients.
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